ArticleFrontiers in microbiology2025
Identification of early prediction biomarkers of severity in patients with severe fever with thrombocytopenia syndrome based on plasma proteomics.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- tRNA-derived small RNA, tsRNA-5017b, as a novel biomarker for predicting severity in severe fever with thrombocytopenia syndrome.Microbiology spectrum · 2026Article
- Unraveling the complexities: A comprehensive review of severe fever with thrombocytopenia syndrome and its associated complications.iScience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerging infectious disease. Given its rapid disease progression and high mortality rate, early warning is crucial in improving the outcomes, However, to date, relevant comprehensive predictors or an effective prediction model are still poorly explored. Methods: A plasma proteomic profile was performed at early stages in patients with SFTS. Functional clustering analysis was used to select the candidate proteins and then validate their expression by ELISA. A cohort consisting of 190 patients with SFTS was used to develop the predictive model for severe illness and subsequently validate it in a new cohort consisting of 93 patients with SFTS. Results: A significant increase in plasma proteins associated with various functional clusters, such as the proteasomal protein catabolic process, phagocytosis, and humoral immune response, was observed in severe SFTS patients. High levels of four proteins including NID1, HSP90α, PSMA1, and VCAM1 were strongly correlated with multi-organ damage and disease progression. A prediction model was developed at the early stage to accurately predict severe conditions with the area under the curve of 0.931 (95% CI, 0.885, 0.963). Conclusion: The proteomic signatures identified in this study provide insights into the potential pathogenesis of SFTS. The predictive models have substantial clinical implications for the early identification of SFTS patients who may progress to severe conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.